Stockholm 13:57
-0,99% Idag
+25,04% Sedan årsskifte
-0,01% OMXSPI

2019-11-05 08:00:00

BioArctic presents Nomination Committee and publishes financial calendar 2020

Stockholm, Sweden, November 5, 2019 - The Annual General Meeting of BioArctic AB on May 9, 2019, adopted instructions regarding the appointment of the Nomination Committee. Pursuant to these instructions the company shall have a Nomination Committee comprising one representative for each of the three largest shareholders in terms of votes based on the share register received from Euroclear Sweden AB on the last banking day in September 2019, as well as the Chairman of the Board (convener).


The three largest shareholders are Demban AB, Ackelsta AB and Tredje AP-fonden, and together represent approximately 64 percent of the shares and approximately 85 percent of the votes.

The Nomination Committee has been appointed and comprises the following members:
  • Margareta Öhrvall, appointed by Demban AB
  • Claes Andersson, appointed by Ackelsta AB
  • Gunnar Blix, appointed by Tredje AP-fonden

The Nomination Committee shall prepare proposals for the 2020 Annual General Meeting regarding the Chairman of the Meeting, the number of Board members, the fees to be paid to the Chairman of the Board and Board members, election of Board members and Board Chairman, remuneration to the auditor and election of the auditor and, if necessary, a proposal for changes in the instructions to the Nomination Committee.  The Nomination Committee's proposal will be provided in the Notice for the Annual General Meeting 2020 and on BioArctic's website at www.bioarctic.com.

Shareholders wishing to submit a proposal to BioArctic's Nomination Committee can do so by e-mail to: ir@bioarctic.se(label e-mails with "Nomination Committee" in the subject line) or by letter addressed to: BioArctic AB, Att: Nomination Committee, Warfvinges väg 35, SE-112 51 Stockholm, Sweden. In order for proposals to be handled appropriately, they must be received no later than January 15, 2020.

The Annual General Meeting 2020 of BioArctic will be held on Thursday, May 7, 2020 at 5:00 p.m. (CET) in Stockholm. A request to have a matter dealt with at the meeting must be received by February 28, 2020 to be included in the Notice.

The financial calendar for BioArctic AB for 2020 is as follows:

+----------------------+----------------------------------+
|Full year report 2019 |February 6, 2020, at 8:00 a.m. CET|
+----------------------+----------------------------------+
|Publication of the |Week commencing March 30, 2020 |
|Annual Report 2019 | |
|(Swedish) | |
+----------------------+----------------------------------+
|Interim report January|April 22, 2020, at 8:00 a.m. CET |
|- March 2020 | |
+----------------------+----------------------------------+
|Annual General Meeting|May 7, 2020, at 5:00 p.m. CET |
|2020 | |
+----------------------+----------------------------------+
|Interim report January|July 10, 2020 at 8:00 a.m. CET |
|- June 2020 | |
+----------------------+----------------------------------+
|Interim report January|October 14, 2020 at 8:00 a.m. CET |
|- September 2020 | |
+----------------------+----------------------------------+

 

For more information, please contact:
Jan Mattsson, CFO
Telephone: +46 70 352 27 72
E-mail: jan.mattsson@bioarctic.se

This information was submitted for publication at 08:00 a.m. CET on November 5, 2019.

About BioArctic
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic's B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). www.bioarctic.com




Attached html: HTML
Attached pdf: PDF